文献速递甲状腺疾病

甲基化介导的ATF3沉默通过调控MAPK和PI3K/AKT通路中的预后基因促进甲状腺癌进展

Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways.
PubMed 文献 · Thyroid · 2023-10-27

研究纳入80例甲状腺乳头状癌(PTC)患者及癌症基因组图谱中510例PTC样本,分析ATF3表达与预后。ATF3在PTC中显著下调,低表达者无进展生存期缩短(校正风险比=0.50[CI 0.26-0.98],p=0.043)。启动子DNA高甲基化破坏SP1和MYC-MAX结合导致ATF3失活,ATF3作为抑癌基因抑制甲状腺癌细胞增殖和迁移,并通过结合调控元件调节MAPK和PI3K/AKT通路中预后相关基因表达。

要点

  • ATF3在PTC中显著下调,低表达与无进展生存期缩短相关(校正风险比=0.50[CI 0.26-0.98],p=0.043)。
  • ATF3启动子DNA高甲基化破坏SP1和MYC-MAX结合,导致基因失活。
  • ATF3作为抑癌基因抑制甲状腺癌细胞增殖和迁移,并调控MAPK和PI3K/AKT通路预后相关基因。

核心结论

  • 启动子DNA高甲基化降低ATF3表达,进而至少部分通过直接调控MAPK和PI3K/AKT通路中的预后相关基因促进甲状腺癌进展。

研究设计与样本

  • 研究利用中山大学附属第一医院80例甲状腺乳头状癌(PTC)患者数据和癌症基因组图谱甲状腺癌数据库中510例PTC样本进行基因表达和预后分析。
  • 生存数据采用Kaplan-Meier曲线和Cox回归分析,校正年龄、性别、多灶性、甲状腺外侵犯、淋巴结转移和新辅助治疗史。
  • DNA甲基化采用甲基化特异性聚合酶链反应(PCR)和亚硫酸氢盐测序PCR分析。
  • 通过DNA pull-down联合质谱鉴定结合ATF3启动子的转录因子,并用定量PCR、荧光素酶报告实验和染色质免疫沉淀(ChIP)-qPCR确认。
  • 体外功能实验和异种移植小鼠模型评估ATF3在甲状腺癌中的功能,基于RNA测序、ChIP-seq和CUT&Tag检测进行整合分析探索机制。

主要发现

  • ATF3在PTC中显著下调,低ATF3表达患者无进展生存期缩短(校正风险比=0.50[CI 0.26-0.98],p=0.043)。
  • ATF3启动子DNA高甲基化破坏SP1和MYC-MAX结合,导致基因失活。
  • ATF3作为抑癌基因抑制甲状腺癌细胞增殖和迁移。
  • ATF3通过结合靶基因调控元件调节其表达,尤其影响MAPK和PI3K/AKT通路基因。
  • 靶基因中,细丝蛋白C受ATF3正向调控并与较好甲状腺癌预后相关,而双特异性磷酸酶10、纤连蛋白1、腱生蛋白C和CREB5受ATF3负向调控并与较差预后相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Aberrant expression of oncogenes and/or tumor suppressor genes (TSGs) drives the tumorigenesis and development of thyroid cancer. We investigated the expression and function of a member of the activating transcription factor (ATF)/cAMP-responsive element-binding protein (CREB) transcription factor (TF) family, ATF3, in thyroid cancer. Methods: Data from 80 patients with papillary thyroid cancer (PTC) in the First Affiliated Hospital of Sun Yat-sen University and 510 PTC samples in The Cancer Genome Atlas thyroid cancer database were utilized for gene expression and prognosis analyses. The survival data were analyzed by Kaplan-Meier curves and Cox regression with adjustment for age, sex, multilocality, extrathyroidal extension, lymph metastases, and history of neoadjuvant treatment. DNA methylation was analyzed by methylation-specific polymerase chain reaction (PCR) and bisulfite sequencing PCR. TFs binding to ATF3 promoter were identified by DNA pull-down combined with mass spectrum assay, and confirmed by quantitative PCR (qPCR), luciferase reporter assay, and chromatin immunoprecipitation (ChIP)-qPCR. We conducted functional assays in vitro and in a xenograft mouse model to evaluate the function of ATF3 in thyroid cancer. Integrated analyses based on RNA sequencing, ChIP-seq, and CUT&Tag assays were performed to explore the mechanisms underlying the function of ATF3. Results: ATF3 was significantly downregulated in PTC and patients with low ATF3 expression had reduced progression-free survival (adjusted hazard ratio = 0.50 [CI 0.26-0.98], p = 0.043). DNA hypermethylation in ATF3 promoter disrupted the binding of SP1 and MYC-MAX, leading to inactivation of the gene. ATF3 functioned as a TSG by inhibiting the proliferation and mobility of thyroid cancer cells. And ATF3 regulated the expression of a number of genes by binding to the regulatory elements of them, particularly for genes in MAPK and PI3K/AKT pathways. Among these target genes, filamin C was positively regulated by ATF3 and associated with a more favorable thyroid cancer prognosis, while dual specificity phosphatase 10, fibronectin-1, tenascin C, and CREB5 were negatively regulated by ATF3 and associated with a poorer prognosis. Conclusions: We observed that the promoter DNA hypermethylation decreased the expression of ATF3, which in turn promoted the progression of thyroid cancer, at least partially, by directly regulating prognosis-related genes in the MAPK and PI3K/AKT pathways.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Xiao X, Chen M, Sang Y, et al. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways. Thyroid. 2023. PMID: 37742107. doi:10.1089/thy.2023.0157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。